ArticleOncology letters2026
Weekly cisplatin and nab-paclitaxel neoadjuvant chemoradiotherapy increases pathological complete response in locally advanced esophageal squamous cell carcinoma: A real-world study.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although neoadjuvant chemoradiotherapy (nCRT) is the standard treatment regimen for patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC), no consensus exists regarding the optimal chemotherapy regimen. The present study aimed to compare the safety/efficacy of weekly (QW) vs. triweekly (Q3W) cisplatin/nab-paclitaxel nCRT in LA-ESCC. This retrospective study analyzed 136 patients with LA-ESCC who underwent esophagectomy after nCRT (QW, n=32; Q3W, n=104). The data included pathological complete response (pCR), major pathological response (MPR), toxicity, survival and postoperative outcomes. The results demonstrated that QW exhibited significantly higher pCR (56.25 vs. 33.65%; P=0.022) and MPR (81.25 vs. 61.54%; P=0.039) rates than Q3W. Hematological toxicity rates were lower for QW, including neutropenia of all grades (46.88% vs. 70.81%, P=0.0001) and thrombocytopenia of all grades (18.75% vs. 31.73%, P=0.033). Grade ≥3 leukopenia (18.75 vs. 51.92%; P=0.001) and grade ≥3 neutropenia (15.62 vs. 38.46%; P=0.016) were less frequent in QW. In addition, the incidence of acute pneumonia of all grades was also lower (0% vs. 16.35%, P>0.05). However, survival outcomes were comparable between the groups, including 1-year overall survival (QW vs. Q3W, 96.6 vs. 100.0%) and progression-free survival (86.5 vs. 85.6%) rates (P>0.05). In conclusion, QW cisplatin/nab-paclitaxel nCRT achieved superior pCR rates and reduced hematological toxicity compared with Q3W dosing in LA-ESCC, thus suggesting its potential use as a safer and more effective neoadjuvant regimen. The survival benefit remains to be validated with an extended follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.